
The first transcatheter device designed to deliver

The Right Solution for the Right Side







Tricuspid regurgitation is largely undertreated.

Patient mortality is significant.

<1% are treated surgically 1*

>36% one-year mortality rate for patients with severe tricuspid regurgitation²

- Many patients diagnosed with tricuspid regurgitation are medically managed
- Patients may experience debilitating symptoms, with few treatment options

^{*} Based on US data.

The first-ever, CE Marked transcatheter tricuspid annular reduction system

Cardioband Tricuspid Valve Reconstruction System.

Designed to safely and effectively reduce tricuspid regurgitation through annular reduction.³

- Restores valve to a more functional state, facilitating leaflet coaptation
- **Enables** annular reduction based on each patient's anatomy
- > **Supports** real-time adjustment and confirmation of procedural results




Facilitates leaflet coaptation. Preserves native anatomy.


Cardioband Tricuspid System addresses the main physiological cause of tricuspid regurgitation: annular dilatation.

 Supra-annular fixation preserves native anatomy keeping future treatment options open

Real-time intraprocedural adjustment and confirmation of results



ECHO AT BASELINE
Transesophageal echocardiogram (TEE) shows tricuspid regurgitation at baseline



ECHO POST-PROCEDUREReal-time, intra-procedural confirmation of reduction in tricuspid regurgitation

A reproducible and standardised procedure.

Precise positioning in patient anatomy

1. Access

Insert Cardioband delivery system into the right atrium using a transfemoral approach.



2. Deploy

Deploy implant via a steerable catheter to navigate around the tricuspid annulus, securing the implant with stainless steel anchors.



3. Adjust and Reduce TR

Introduce the size adjustment tool over a wire and rotate the adjustment knob clockwise for implant contraction.




Clinical results show the Cardioband Tricuspid System safely and effectively reduces tricuspid regurgitation and improves quality of life.³





Edwards Cardioband Tricuspid Valve Reconstruction System



Driven by a passion to help patients.

With the first-ever introduction of an advanced, CE Marked transcatheter solution for the treatment of tricuspid regurgitation, Edwards Lifesciences continues to innovate in meaningful and lasting ways for both physicians and patients.

For more information, please visit www.edwards.com/CardiobandTR

References

- Fender EA, Zack CJ, Nishimura RA. Isolated tricuspid regurgitation: outcomes and therapeutic interventions. Heart. 2017; doi:10.1136/heartjnl-2017-311586.
- $2. \quad Nath \ J, Foster \ E, Heidenreich \ PA. \ Impact of tricuspid \ regurgitation \ on \ long-term \ survival. \ J. Am \ Coll \ Cardiol. \ 2004; 43:405-409.$
- 3. Nickenig G. TRI-REPAIR: 30-day outcomes of transcatheter TV repair in patients with severe secondary tricuspid regurgitation. Presented at TCT 2017; Denver, CO.

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards, Edwards Lifesciences, the stylized E logo, Cardioband, Valtech, and Valtech Cardio are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

 $\hbox{@ 2020 Edwards Lifesciences Corporation.}$ All rights reserved. PP--EU-0189 v1.0

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com

